X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3037) 3037
Book Review (418) 418
Publication (277) 277
Conference Proceeding (20) 20
Book Chapter (19) 19
Book / eBook (16) 16
Magazine Article (10) 10
Dissertation (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2690) 2690
animals (1699) 1699
male (1653) 1653
humans (1574) 1574
parkinson's disease (1439) 1439
neurosciences (1362) 1362
parkinsonian disorders - drug therapy (1360) 1360
female (997) 997
rats (811) 811
clinical neurology (809) 809
parkinsonian disorders - physiopathology (798) 798
disease models, animal (756) 756
parkinsonian disorders - chemically induced (695) 695
parkinsonian disorders - metabolism (618) 618
parkinsonian disorders - pathology (582) 582
neurology (550) 550
disease (523) 523
middle aged (518) 518
mice (512) 512
aged (493) 493
parkinsons-disease (476) 476
dopamine (456) 456
dopamine - metabolism (436) 436
rats, sprague-dawley (435) 435
parkinsonism (372) 372
basal ganglia (370) 370
neurons (366) 366
substantia-nigra (353) 353
antiparkinson agents - therapeutic use (345) 345
pharmacology & pharmacy (322) 322
adult (317) 317
levodopa - therapeutic use (313) 313
mice, inbred c57bl (313) 313
oxidopamine (303) 303
analysis (301) 301
corpus striatum - drug effects (299) 299
motor activity - drug effects (296) 296
parkinsonian disorders - diagnosis (292) 292
brain (291) 291
substantia nigra - drug effects (286) 286
parkinsonian disorders (281) 281
corpus striatum - metabolism (272) 272
parkinsonian disorders - complications (266) 266
mptp (264) 264
neurons - drug effects (263) 263
movement disorders (261) 261
neuroprotective agents - pharmacology (259) 259
antiparkinson agents - pharmacology (258) 258
parkinsonian disorders - therapy (256) 256
dose-response relationship, drug (254) 254
rats, wistar (253) 253
psychiatry (252) 252
tyrosine 3-monooxygenase - metabolism (246) 246
parkinsonian disorders - genetics (241) 241
parkinson’s disease (237) 237
oxidative stress (235) 235
neurons - metabolism (234) 234
6-hydroxydopamine (233) 233
substantia nigra - metabolism (217) 217
l-dopa (216) 216
levodopa (214) 214
substantia nigra - pathology (212) 212
treatment outcome (208) 208
levodopa - pharmacology (205) 205
levodopa - adverse effects (203) 203
neuroprotection (202) 202
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (196) 196
oxidopamine - toxicity (195) 195
parkinsons disease (186) 186
dyskinesia (183) 183
parkinson disease (183) 183
diagnosis (182) 182
nervous system diseases (180) 180
neurodegeneration (179) 179
antiparkinson agents - adverse effects (176) 176
brain - pathology (175) 175
time factors (175) 175
brain - drug effects (174) 174
striatum (173) 173
dopaminergic-neurons (172) 172
alpha-synuclein (169) 169
immunohistochemistry (167) 167
nervous system (163) 163
aged, 80 and over (162) 162
parkinsonian disorders - etiology (162) 162
parkinson disease - drug therapy (158) 158
article (157) 157
brain - metabolism (156) 156
behavior, animal - drug effects (154) 154
biochemistry & molecular biology (153) 153
neuroprotective agents - therapeutic use (153) 153
diagnosis, differential (152) 152
magnetic resonance imaging (152) 152
corpus striatum - pathology (151) 151
neurons - pathology (151) 151
drug therapy (148) 148
neurodegenerative diseases (148) 148
substantia nigra (145) 145
multiple system atrophy (144) 144
phenols (143) 143
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2938) 2938
German (33) 33
French (30) 30
Japanese (21) 21
Spanish (17) 17
Russian (14) 14
Swedish (5) 5
Norwegian (3) 3
Turkish (3) 3
Chinese (2) 2
Hungarian (2) 2
Italian (2) 2
Portuguese (2) 2
Bosnian (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | Index Medicus
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 2014, Volume 34, Issue 27, pp. 9124 - 9133
Patients with Parkinson's disease (PD) display significant sleep disturbances and daytime sleepiness. Dopaminergic treatment dramatically improves PD motor... 
Sleep disorders | Parkinson's disease | L-dopa | Cholinergic neurons | Macaques | Pedunculopontine nucleus | BEHAVIOR DISORDER | sleep disorders | pedunculopontine nucleus | MODEL | NEUROSCIENCES | DOPAMINERGIC TREATMENT | cholinergic neurons | MESOPONTINE TEGMENTUM | MPTP-TREATED MONKEYS | DISEASE | macaques | EXCESSIVE DAYTIME SLEEPINESS | PROGRESSIVE SUPRANUCLEAR PALSY | REM-SLEEP | Sleep Disorders, Intrinsic - etiology | Parkinsonian Disorders - complications | Sleep, REM - physiology | Pedunculopontine Tegmental Nucleus - injuries | MPTP Poisoning - physiopathology | Macaca fascicularis | Male | Sleep Disorders, Intrinsic - physiopathology | Benserazide - pharmacology | Diphtheria Toxin - toxicity | MPTP Poisoning - complications | Parkinsonian Disorders - drug therapy | Sleep Deprivation - etiology | Diphtheria Toxin - genetics | Sleep, REM - drug effects | Levodopa - pharmacology | Parkinsonian Disorders - physiopathology | Sleep Deprivation - drug therapy | Muscle Tonus - physiology | Pedunculopontine Tegmental Nucleus - physiopathology | Levodopa - therapeutic use | Sleep Disorders, Intrinsic - drug therapy | Urotensins - genetics | Benserazide - therapeutic use | Recombinant Fusion Proteins - toxicity | Muscle Tonus - drug effects | Cholinergic Neurons - drug effects | MPTP Poisoning - drug therapy | Polysomnography | Sleep Deprivation - physiopathology | Animals | Wakefulness - physiology | Drug Combinations | Index Medicus | l-dopa
Journal Article
Movement Disorders, ISSN 0885-3185, 01/2007, Volume 22, Issue 2, pp. 193 - 197
We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement... 
tetrabenazine | chorea | tics | tolerability | tardive dyskinesia | Tics | Tolerability | Tardive dyskinesia | Tetrabenazine | Chorea | OPEN-LABEL | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | TOURETTES-SYNDROME | DRUGS | NEUROLEPTIC MALIGNANT SYNDROME | DOUBLE-BLIND | TARDIVE-DYSKINESIA | HUNTINGTONS-DISEASE | BRAIN | Prevalence | Dyskinesia, Drug-Induced - physiopathology | Humans | Middle Aged | Drug Tolerance - physiology | Male | Hyperkinesis - physiopathology | Time | Hyperkinesis - drug therapy | Tics - epidemiology | Myoclonus - drug therapy | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Adult | Female | Anti-Dyskinesia Agents - administration & dosage | Retrospective Studies | Huntington Disease - physiopathology | Severity of Illness Index | Tetrabenazine - administration & dosage | Parkinsonian Disorders - physiopathology | Dyskinesia, Drug-Induced - epidemiology | Drug Administration Schedule | Parkinsonian Disorders - epidemiology | Huntington Disease - etiology | Myoclonus - physiopathology | Anti-Dyskinesia Agents - therapeutic use | Huntington Disease - epidemiology | Anti-Dyskinesia Agents - adverse effects | Age of Onset | Tetrabenazine - adverse effects | Hyperkinesis - epidemiology | Myoclonus - epidemiology | Tics - drug therapy | Tics - physiopathology | Tetrabenazine - therapeutic use | Index Medicus
Journal Article
Biological Psychiatry, ISSN 0006-3223, 2014, Volume 75, Issue 9, pp. 711 - 722
Background L-3,4-dihydroxyphenylalanine (L-DOPA)–induced dyskinesia is an incapacitating complication of L-DOPA therapy that affects most patients with... 
Psychiatry | three-dimensional neuronal reconstruction | medium spiny neuron | striatum | Behavioral sensitization | L-DOPA | dyskinesia | Parkinson’s disease | Parkinson's disease | RAT NEOSTRIATUM | HEMIPARKINSONIAN MICE | PSYCHIATRY | D-1 | NEUROSCIENCES | NUCLEUS-ACCUMBENS | DENDRITIC SPINES | LEVODOPA-INDUCED DYSKINESIA | STRIATAL NEURONS | EXPRESSION | PARKINSONS-DISEASE | Neurons - pathology | Dyskinesia, Drug-Induced - physiopathology | Cerebral Cortex - pathology | Male | Oxidopamine | Receptors, Dopamine D2 - metabolism | Cerebral Cortex - physiopathology | Receptors, Dopamine D1 - metabolism | Antiparkinson Agents - therapeutic use | Dendritic Spines - drug effects | Parkinsonian Disorders - drug therapy | Neurons - physiology | Receptors, Dopamine D1 - agonists | Cerebral Cortex - drug effects | Neurons - drug effects | Corpus Striatum - pathology | Membrane Potentials - drug effects | Dopamine Agonists - pharmacology | Parkinsonian Disorders - physiopathology | Corpus Striatum - physiopathology | Levodopa - therapeutic use | Mice, Inbred C57BL | Dendritic Spines - physiology | Proto-Oncogene Proteins c-fos - metabolism | Mice, Transgenic | Dyskinesia, Drug-Induced - pathology | Membrane Potentials - physiology | Antiparkinson Agents - adverse effects | Animals | Parkinsonian Disorders - pathology | Dendritic Spines - pathology | Levodopa - adverse effects | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology | Corpus Striatum - drug effects | Phenols | Dopamine | Dopa | Neurons | Movement disorders | Resveratrol | Index Medicus
Journal Article
Acta Neuropathologica, ISSN 0001-6322, 9/2015, Volume 130, Issue 3, pp. 333 - 348
Parkinson disease (PD) is a neurodegenerative disorder characterized by massive loss of midbrain dopaminergic neurons. Whereas onset of motor impairments... 
Pathology | Neurosciences | Braak stages | Medicine & Public Health | Neurodegeneration | Hyposmia | Olfactory perception | Parkinson disease | Olfactory bulbectomy | ADULT NEUROGENESIS | SUBVENTRICULAR ZONE | PATHOLOGY | PARKINSONS-DISEASE PATIENTS | SUBSTANTIA-NIGRA | NEUROSCIENCES | PRECURSOR CELL-PROLIFERATION | CLINICAL NEUROLOGY | RECEPTOR STIMULATION | ALPHA-SYNUCLEINOPATHY | BULB | NEURONS | BRAIN | Immunohistochemistry | Neurons - pathology | Neural Pathways - drug effects | Rats, Wistar | Substantia Nigra - pathology | Neuroanatomical Tract-Tracing Techniques | Male | Olfactory Bulb - metabolism | Neural Pathways - pathology | Substantia Nigra - metabolism | Oxidopamine | Parkinsonian Disorders - metabolism | Olfaction Disorders - metabolism | Parkinsonian Disorders - drug therapy | Neurogenesis - drug effects | Neurons - metabolism | Neurons - drug effects | Dopamine - metabolism | Dopamine Agonists - pharmacology | Olfaction Disorders - pathology | Olfactory Bulb - pathology | Neural Stem Cells - drug effects | Thiophenes - pharmacology | Neural Stem Cells - pathology | Olfaction Disorders - drug therapy | Substantia Nigra - drug effects | Animals | Parkinsonian Disorders - pathology | Neurogenesis - physiology | Tetrahydronaphthalenes - pharmacology | Neural Pathways - metabolism | Neural Stem Cells - metabolism | Olfactory Bulb - drug effects | Neuronal Tract-Tracers | Physiological aspects | Nervous system diseases | Parkinson's disease | Index Medicus
Journal Article
Neuropharmacology, ISSN 0028-3908, 06/2014, Volume 81, pp. 142 - 152
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2010, Volume 39, Issue 3, pp. 423 - 438
Abstract Tauopathies are neurodegenerative diseases, sporadic or familial, mainly characterized by dementia and parkinsonism associated to atrophy of the... 
Neurology | Tauopathies | Parkinson's disease | Dopamine | Trehalose | Tau | Autophagy | Parkin | RAT-LIVER | OXIDATIVE STRESS | ALZHEIMERS-DISEASE | AXONAL-TRANSPORT | ALPHA-SYNUCLEIN | CELL-SURVIVAL | NEUROSCIENCES | MONITORING AUTOPHAGY | MITOCHONDRIAL DYSFUNCTION | 4-REPEAT TAU | TRANSGENIC MICE | Neurons - pathology | Neurofibrillary Tangles - genetics | Tauopathies - genetics | Mesencephalon - metabolism | Dopamine - genetics | Tauopathies - pathology | Corpus Striatum - metabolism | Autophagy - drug effects | Parkinsonian Disorders - metabolism | Neurofibrillary Tangles - metabolism | tau Proteins - genetics | Parkinsonian Disorders - drug therapy | Trehalose - therapeutic use | Polymerase Chain Reaction | Mesencephalon - drug effects | Parkinsonian Disorders - genetics | Neurons - metabolism | Neurons - drug effects | Corpus Striatum - pathology | Dopamine - metabolism | Mesencephalon - pathology | Neurofibrillary Tangles - pathology | Genotype | Mice, Transgenic | Tauopathies - metabolism | Animals | Parkinsonian Disorders - pathology | Corpus Striatum - drug effects | Mice | Tauopathies - drug therapy | Ubiquitin-Protein Ligases - genetics | Trehalose - pharmacology | Nervous system diseases | Neurons | Animal behavior | Analysis | Amyloid beta-protein | Heat shock proteins | Hydroxylases | Sugars | Dementia | Index Medicus
Journal Article
Journal Article
Antioxidants & Redox Signaling, ISSN 1523-0864, 06/2011, Volume 14, Issue 12, pp. 2347 - 2360
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 03/2003, Volume 84, Issue 6, pp. 1398 - 1410
We have examined the ability of KW‐6002, an adenosine A 2a antagonist, to modulate the dyskinetic effects of l ‐DOPA in 6‐hydroxydopamine‐lesioned rats. In... 
movement disorder | Parkinson's disease | striatopallidal | indirect pathway | striatonigral | opioid | Indirect pathway | Opioid | Striatopallidal | Striatonigral | Movement disorder | Purinergic P1 Receptor Antagonists | Enkephalins - metabolism | Parkinsonian Disorders - complications | Motor Activity - drug effects | Oxidopamine | RNA, Messenger - metabolism | Corpus Striatum - metabolism | Enkephalins - genetics | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Behavior, Animal - drug effects | Female | Drug Therapy, Combination | Disease Models, Animal | Dyskinesia, Drug-Induced - complications | Protein Precursors - genetics | Purines - pharmacology | Proto-Oncogene Proteins c-fos - metabolism | Rats | Treatment Outcome | Parkinsonian Disorders - chemically induced | Rats, Sprague-Dawley | Receptor, Adenosine A2A | Protein Precursors - metabolism | Animals | Levodopa - adverse effects | Corpus Striatum - drug effects | Index Medicus | Disease Models | Neurosciences | RNA | Medical and Health Sciences | Medicin och hälsovetenskap | Drug-Induced: complications | Drug-Induced: drug therapy | Purinergic P1: antagonists & inhibitors | Levodopa: adverse effects | Proto-Oncogene Proteins c-fos: metabolism | Corpus Striatum: drug effects | Sprague-Dawley | Receptors | Enkephalins: metabolism | Combination | Corpus Striatum: metabolism | Protein Precursors: metabolism | Behavior | Animal: drug effects | Dyskinesia | Neurovetenskaper | Basic Medicine | Drug Therapy | Parkinsonian Disorders: complications | Messenger: metabolism | Motor Activity: drug effects | Enkephalins: genetics | Animal | Parkinsonian Disorders: chemically induced | Medicinska och farmaceutiska grundvetenskaper | Purines: pharmacology | Parkinsonian Disorders: drug therapy | Protein Precursors: genetics
Journal Article